Cardiac Biomarkers: Innovations in Diagnostics and Prognostics

Novel approach to proficiency testing allows insight into areas for improvement in non-small cell lung cancer biomarker analysis

, 20 August 2025/in Featured Articles, Cardiac Biomarkers /by panglobal

Although great developments have been made in treating lung cancer, it remains the most common cause of cancer deaths, largely because patients present late with advanced disease. Timely and accurate reporting of biomarker analysis is crucial for directing physicians to the most appropriate therapy for the patient. CLI chatted to Dr Brandon Sheffield (molecular pathologist […]

Prognostic value of circulating biomarkers in men compared to women presenting with acute chest pain

, 19 March 2025/in Featured Articles, Cardiac Biomarkers /by panglobal

by Dr Gard Myrmel We have known for a while now that the symptoms of acute coronary syndromes can be different for women compared to men. Here, Dr Myrmel discusses how the differences between the sexes also extend to the prognostic value of circulating biomarkers in patients presenting with acute chest pain.

Macrotroponin: potential source of cardiac troponin assay interference

, 18 March 2025/in Cardiac Biomarkers, Featured Articles /by panglobal

by PD Dr Angelika Hammerer-Lercher Measurement of cardiac-specific troponin I or T forms is part of the diagnostic pathway to rule in or rule out acute coronary syndromes, such as heart attack, as well as for prognostication of future cardiovascular disease. CLI chatted to Dr Angelika Hammerer-Lercher (Chief Physician and Director of Central Medical Laboratories, […]

Impact of glycosylation on NT-proBNP immunoassay performance

, 16 March 2025/in Featured Articles, Cardiac Biomarkers /by panglobal

by Dr Aleksandra Havelka Assays for NT-proBNP form a key part of diagnosing/ruling out, predicting and managing heart failure. CLI chatted to Dr Aleksandra Havelka (Gentian Diagnostics) to find out more about the challenges and limitations of measuring NT-proBNP concentrations, particularly the effects of glycosylation, and what developments are on the horizon to overcome these […]

Novo Nordisk to acquire Cardior Pharmaceuticals and their lead compound CDR132L for heart failure

, 7 June 2024/in Cardiac Biomarkers, E-News /by panglobal

Novo Nordisk will acquire Cardior Pharmaceuticals for up to €1.025 billion, including an upfront payment and additional payments if certain development and commercial milestones are achieved.

Biomarkers in heart failure | Beyond laboratory values

, 12 March 2024/in Cardiac Biomarkers, Featured Articles /by panglobal

by Dr Roopa Rao and Arden Shen The incidence of heart failure (HF) is increasing globally. Biomarkers in HF play a key role in diagnosis and prognostication. Ideal biomarkers should be easily measurable with distinct values in normal physiology, disease state and be a marker of therapeutic intervention. Several biomarkers have emerged that are potentially […]